Key result
Administration of the fixed-dose combination of amlodipine/indapamide/perindopril arginine without additional antihypertensive agents significantly decreased office blood pressure by 36/17 mm Hg and achieved target blood pressure in 88.4% of patients after 3 months.
Why the study?
To analyze the efficacy and tolerability of amlodipine/indapamide/perindopril arginine without other antihypertensive agents in patients participating in the Russian observational program DOKAZATEL`STVO.
Does a fixed-dose combination of amlodipine/indapamide/perindopril arginine reduce blood pressure in patients with hypertension?
Observational (n=790)
Open-label
Yes
Does a fixed-dose combination of amlodipine/indapamide/perindopril arginine reduce blood pressure in patients with hypertension?
Mean Difference: -36.2
Absolute Event Rate: 127.2% vs 163.4%
p-value: p=<0.001
A fixed-dose combination of amlodipine/indapamide/perindopril arginine effectively and safely reduces blood pressure in patients with hypertension in a real-world setting.
Supports real-world BP control with this triple combination; hypothesis-generating pending randomized trials.
Aim . To analyze the efficacy and tolerability of amlodipine/indapamide/perindopril arginine (Triplixam) in a subgroup of 790 people participating in the Russian observational program DOKAZATEL`STVO without use of other antihypertensive agents. Material and methods . The analysis included 790 patients with hypertension (HTN) (men — 37,9%, mean age — 60,0±10,2 years). The drug was administrated in one of 4 recommended dosages for 3 months. We assessed the dynamics of office and home blood pressure (BP) from visit 1 to visit 4 and the frequency of achieving the target BP <140/90 mm Hg in 3 months. Results . After 3 months, office systolic BP (SBP) decreased from 163,4±14,0 to 127,2±7,8 mm Hg, diastolic BP (DBP) — from 95,7±9,5 to 78,3±6,2 mm Hg (p 0,001). Home SBP in the morning decreased from 145,9±12,3 to 128,3±7,8 mm Hg, DBP — from 86,2±7,7 to 78,4±5,6 mm Hg (p<0,001). After 3 months, target office BP (<140/90 mm Hg) was achieved in 88,4% of subjects, home BP (<135/85 mm Hg) — 73%. Conclusion . The administration of Triplixam without additional antihypertensive agents results in a significant BP decrease by 36/17 mm Hg and rapid achievement of BP control in most patients. The combination is safe and well tolerated.
No takes yet. Share an insight, caveat, or question.
Kobalava et al. (2020) conducted an observational in Hypertension (n=790). Amlodipine/indapamide/perindopril arginine (Triplixam) vs. Baseline (no control group) was evaluated on Change in office systolic blood pressure (SBP) from baseline to 3 months (MD -36.2 mm Hg, p=<0.001). Administration of the fixed-dose combination of amlodipine/indapamide/perindopril arginine without additional antihypertensive agents significantly decreased office blood pressure by 36/17 mm Hg and achieved target blood pressure in 88.4% of patients after 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: